Hyloris Raises €80m For Business Development
Company Anticipates First European Approval
Executive Summary
With the main aim of developing its existing product portfolio and pursuing business development opportunities in the US, Hyloris Pharmaceuticals has successfully raised €80m through a public listing. The company has announced its financial results for the first half of 2020.